Endocrinology, Diabetes & Metabolism Doctors in Rockford, IL Accepting Medicare

5 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 5

Dr. Amrutha Mary George, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1253 N Alpine Rd, Rockford, IL 61107 Phone: 779-696-9201

Dr. Paul E Reith, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2300 N Rockton Ave, Main Clinic - Endo Dept., Rockford, IL 61103 Phone: 815-971-2000

Joeseph Pittman, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1200 W State St, Rockford, IL 61102 Phone: 815-490-1600

Aliya S. Naseer, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2300 N Rockton Ave, Rockford, IL 61103 Phone: 815-971-2000

John Garry Hovis, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2300 N Rockton Ave, Rockford, IL 61103 Phone: 815-971-2000

News Archive

Barr confirms patent challenge of Ritalin LA

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.

Symposium to address complex issues surrounding water and health

On November 13, the Johns Hopkins Bloomberg School of Public Health and the New York Academy of Sciences will host a symposium to address the complex issues surrounding water and health.

Female health care volunteers in Nepal helping to improve maternal, neonatal survival rates

"Women working as female health care volunteers [FHCVs] often provide a vital service for the poorest in mountainous Nepal, and have contributed to a steady improvement in maternal and neonatal survival rates," IRIN reports.

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

Read more Medical News

› Verified 2 days ago